Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States

Abstract

This review will compare and contrast the costs and access to novel drugs for treating chronic lymphocytic leukemia (CLL) and lymphoma in the United States and India during the last 5 years. Clinical outcomes for patients with hematologic malignancies have improved significantly since the approval of immunotherapeutic and targeted therapies. These new treatments have had an impact on overall outcomes and have helped determine the design for translational research and future trials. Although most of these novel drugs called “innovators” are initially approved and marketed in the United States, several have also become available in countries such as India. With the expiration of patents, generic versions of innovator drugs have increased and accessibility has improved for patients. The advent of biosimilars is another route for expanding access to biologic compounds. As a result, the development costs for developing these drugs are lower, and consequently, the costs for the patient are often lower. Although the delivery of cancer care is not the same in India as it is in the United States, the introduction of biosimilars and generics has helped bridge the gap. This has made treatment of CLL and lymphoma similar in both countries and has had the same impact on patient outcomes and quality of life. Compulsory licensing for essential medications, as stipulated by the Doha Declaration, and capping of drug prices could improve global access to treatments for CLL and lymphoma.

Trends in Disease Burden of Chronic Lymphocytic Leukemia at the Global, Regional, and National Levels From 1990 to 2019, and Projections Until 2030: A Population-Based Epidemiologic Study

“…Unfortunately, access to the novel agents is currently limited to certain developed countries, and every effort should be made to make sure patients in developing countries also benefit from these outstanding drugs ( 12 ). Most novel drugs and targeted drugs approved by the US Food and Drug Administration (FDA) and marketed in the United States are not available in developing countries such as India ( 52 ). In a resource-limited hospital in Nigeria, the major first-line chemotherapy used was cyclophosphamide, vincristine, and prednisolone (CVP) for 42.9% of patients, followed by chlorambucil and prednisolone (CP) for 31.4%.…”

The global burden of childhood and adolescent leukaemia and attributable risk factors: An analysis of the Global Burden of Disease Study 2019

“…Previous studies have shown that the survival rate of leukaemia cancer in children at different economic levels and countries is different due to the difference in treatment level, professional medical care, and malignant tumour prevention plan [31]. The development of drugs alleviates the death and DALY burden of leukaemia in the high SDI region [32]. Contrastingly, The DALY values for children in low SDI regions are much higher compared to those in high SDI regions.…”

Mapping loneliness through comparative analysis of USA and India using social intelligence analysis

“…The study identified various demographics which are at risk of conditions. V. Sathyanarayanan et al [ 14 ] did a comparative study of access to novel drugs for Lymphoma and Leukemia between USA and India. The study took different parameters into consideration before concluding that the treatment of the conditions has the same impact on quality of life and patient outcomes in both countries.…”